Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...

Bonus Biogroup has received FDA approval for an IND application to conduct a Phase III clinical trial of a drug designed to treat acute respiratory distress syndrome (ARDS), especially in severe COVID ...

Researchers review the ever-growing list of human viruses, examining their diversity, transmission pathways, and the urgent ...

On this day in 2020, the World Health Organization (WHO) named a disease spreading from Wuhan, China, COVID-19. On Feb. 11, ...

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with more rapid progression of coronary ...

Guillain-Barré Syndrome ... Acute Motor Axonal Neuropathy (AMAN): Common in Asia and Central/South America, primarily affects motor nerves. Acute Motor-Sensory Axonal Neuropathy (AMSAN): A severe ...

Findings indicate a sharp drop in immunity after Omicron infection, stressing the necessity for updated vaccines to enhance protection against reinfection.

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% scalp hair loss.

Objectives Anxiety has been suggested to be associated with poor outcomes in patients with acute coronary syndrome (ACS). However, results of previous follow-up studies were inconsistent. The aim of ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022 to 2023 season.

is the most common viral pathogen associated with acute lower respiratory tract infection (LRTI) in children under 5 years of age. Severe RSV disease is associated with the development of chronic ...